Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection

American Journal of Health-System Pharmacy

Volumn 67, Issue 17, 2010, Pages 1417-1425

  Jacobsen, Thomas ^a   Sifontis, Nicole ^b  

^a ViroPharma Incorporated   (United States)

^b TEMPLE UNIVERSITY   (United States)

Author keywords

Antiviral agents; Cidovofir; Cytomegalovirus infections; Dosage; Drug interactions; Foscarnet sodium; Ganciclovir; Globulin immune; Toxicity; Transplantation; Valganciclovir

Indexed keywords

AMIKACIN; CIDOFOVIR; CILASTATIN PLUS IMIPENEM; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; DIDANOSINE; FOSCARNET; GANCICLOVIR; GENTAMICIN; LEFLUNOMIDE; LIVE VACCINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROBENECID; RIFAMPICIN; RITONAVIR; SAQUINAVIR; VALGANCICLOVIR; ZIDOVUDINE; ANTIVIRUS AGENT;

ANEMIA; AREA UNDER THE CURVE; BLEEDING; BONE MARROW SUPPRESSION; COMORBIDITY; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG POTENTIATION; DRUG WITHDRAWAL; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION RATE; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOPENIA; LIVER TOXICITY; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; ORGAN TRANSPLANTATION; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; SEIZURE; SEPSIS; THROMBOCYTOPENIA; DRUG COMBINATION; DRUG INTERACTION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; ORGAN TRANSPLANTATION;

EID: 79952033116     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp090424     Document Type: Review

References (72)

1. Steininger C. Novel therapies for cytomegalovirus. Recent Pat Antiinfect Drug Discov. 2007; 2:53-72.
2. Trofe J, Pote L, Wade E et al. Maribavir: a novel antiviral agent with activity against cytomegalovirus. Ann Pharmacother. 2008; 42:1447-57.
3. Munro SC, Hall B, Whybin LR et al. Diagnosis of and screening for cytomegalovirus infection in pregnant women. J Clin Microbiol. 2005; 43:4713-8. (Pubitemid 41298268)
4. Staras SA, Dollard SC, Radford KW et al. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis. 2006; 43:1143-51.
5. Sinclair J, Sissons P. Latent and persistent infections of monocytes and macrophages. Intervirology. 1996; 39:293-301. (Pubitemid 27174133)
6. Broers AE, van Der Holt R, van Esser JW et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogenic T-cell-depleted stem cell transplantation. Blood. 2000; 95:2240-5. (Pubitemid 30167720)
7. Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004; 4:611-20. (Pubitemid 38523584)
8. Preiksaitis JK, Brennan DC, Fishman J et al. Transplantation consensus workshop on cytomegalovirus management in solid organ transplantation: final report. Am J Transplant. 2005; 5:218-27. (Pubitemid 40179508)
9. Griffiths P, Whitley R, Snydman DR et al. Contemporary management of cytomegalovirus infection in transplant patients: guidelines from an IHMF workshop, 2007. Herpes. 2008; 15:4-12.
10. Eid AJ, Arthurs SK, Deziel PJ et al. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant. 2008; 22:162-70. (Pubitemid 351420009)
11. Jacubeit T, Drisch D, Weber E. Risk factors as reflected by an intensive drug monitoring system. Agents Actions Suppl. 1990; 29:117-25.
12. Leape LL, Bates DW, Cullen DJ et al. Systems analysis of adverse drug events. JAMA. 1995; 274:35-43.
13. Raschetti R, Morgutti M, Menniti-Ippolito F et al. Suspected adverse drug events requiring emergency department visits or hospital admissions. Eur J Clin Pharmacol. 1999; 54:959-63. (Pubitemid 29104418)
14. Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med. 1995; 155:1949-56.
15. Griffen JP, D'Arcy PF. A manual of adverse drug interactions. Amsterdam: Elsevier Science BV; 1997.
16. Zhang L, Strong JM, Qiu W et al. Scientific perspectives on drug transporters and their role in drug interactions. Mol Pharm. 2006; 3:62-9. (Pubitemid 43331752)
17. McInnes GT, Brodie MJ. Drug interactions that matter: a critical reappraisal. Drugs. 1988; 36:83-110.
18. Flockhart DA. Drug interactions: cytochrome P450 drug interaction table, Indiana University School of Medicine 2007. www.medicine.iupui.edu/Flockhart/ table.htm (accessed 2009 Jan 12).
19. McEvoy GK, Snow EK, Miller J et al., eds. AHFS drug information. Bethesda, MD: American Society of Health-System Pharmacists; 2008.
20. Cymevene (ganciclovir) package insert. New South Wales, Australia: Roche Laboratories; 2006 Nov.
21. Czock D, Scholle C, Rasche FM et al. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin Pharmacol Ther. 2002; 72:142-50. (Pubitemid 35034492)
22. Foscavir (foscarnet) package insert. New South Wales, Australia: AstraZeneca; 2006.
23. Ritonavir interaction: renal dysfunction with concomitant foscarnet and saquinavir: 3 case reports. Reactions. 1997; 1:11.
24. Morales JM, Muñoz MA, Fernández Zataraín G et al. Reversible acute renal failure caused by the combined use of foscarnet and cyclosporine in organ transplanted patients. Nephrol Dial Transplant. 1995; 10:882-3.
25. Fan-Harvard P, Sanchorawala V, Oh J et al. Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures. Ann Pharmacother. 1994; 28:869-72. (Pubitemid 24262650)
26. Vistide (cidofovir) package insert. Forest City, CA: Gilead Sciences; 2000.
27. Cytogam (cytomegalovirus immune globulin intravenous) package insert. Bern, Switzerland: CSL Behring AG; 2008 Jul.
28. Ho M. The history of cytomegalovirus and its diseases. Med Microbiol Immunol. 2008; 197:65-73.
29. American Society of Transplantation. Cytomegalovirus. Am J Transplant. 2004; 4(suppl 10):51-8.
30. Levitsky J, Singh N, Wagener MM et al. A survey of CMV prevention strategies after liver transplantation. Am J Transplant. 2008; 8:158-61.
31. Singh N. Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy. Rev Med Virol. 2006; 16:281-7. (Pubitemid 44497309)
32. Snydman DR. The case for cytomegalovirus prophylaxis in solid organ transplantation. Rev Med Virol. 2006; 16:289-95. (Pubitemid 44497310)
33. Faulds D, Heel RC. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs. 1990; 39:597-638.
34. Rubin RH, Kemmerly SA, Conti D et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis. 2000; 2:112-7.
35. Kliem V, Fricke L, Wollbrink T et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant. 2008; 8:975-83. (Pubitemid 351537752)
36. Cytovene-IV (ganciclovir sodium for injection) package insert. South San Francisco, CA: Genentech; 2010 Feb.
37. Jacobson MA, De Miranda P, Gordon SM et al. Prolonged pancytopenia due to combined ganciclovir and zidovudine therapy. J Infect Dis. 1988; 158:489-90.
38. Jacobson MA, Owen W, Campbell J et al. Tolerability of combined ganciclovir and didanosine for the treatment of cytomegalovirus disease associated with AIDS. Clin Infect Dis. 1993; 16(suppl 1):S69-73.
39. Hochster H, Dieterich D, Bozzette S et al. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. Ann Intern Med. 1990; 113:111-7. (Pubitemid 20218628)
40. Malone DC, Hutchins DS, Haupert H et al. Assessment of potential drug-drug interactions with a prescription claims database. Am J Health-Syst Pharm. 2005; 62:1983-91. (Pubitemid 41416234)
41. Mann HJ. Drug-associated disease: cytochrome P450 interactions. Crit Care Clin. 2006; 22:329-45.
42. Hartman NR, Yarchoan R, Thomas RV et al. Effect of different oral preparations and presence of other medications on the pharmacokinetics of 2′,3′-dideoxyinosine. Paper presented at 6th International Conference on AIDS. San Francisco, CA; 1990 Jun 20.
43. Freitas VR, Fraser-Smith EB, Matthews TR. Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo. Antiviral Res. 1989; 12:205-12. (Pubitemid 20006601)
44. Manischewitz JF, Quinnan GV Jr, Lane HC et al. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob Agents Chemother. 1990; 34:373-5. (Pubitemid 20046901)
45. Mattes FM, Hainsworth EG, Geretti AM et al. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J Infect Dis. 2004; 189:1355-61. (Pubitemid 38543583)
46. Valcyte (valganciclovir) package insert. Nutley, NJ: Roche Laboratories; 2003.
47. Jung D, Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol. 1999; 39:800-4. (Pubitemid 30629438)
48. Wiltshire H, Hirankarn S, Farrell C et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet. 2005; 44:495-507. (Pubitemid 40733734)
49. Manuel O, Venetz JP, Fellay J et al. Efficacy and safety of universal valganciclovir prophylaxis combined with a tacrolimus/mycophenolate-based regimen in kidney transplantation. Swiss Med Wkly. 2007; 137:669-76. (Pubitemid 350221801)
50. Undre NA, Van Hooff J, Christians M et al. Pharmacokinetics of FK506 and mycophenolic acid after the administration of a FK506-based regimen in combination with mycophenolate mofetil regimen in kidney transplantation. Transplant Proc. 1998; 30:1299.
51. Fulco PP, Higginson RT, Orenstein RO. Acute pancreatitis associated with the concurrent use of valganciclovir and didanosine (abstract B10396). Paper presented at 8th International Conference on AIDS. Barcelona, Spain; 2002 Jul 7.
52. Chrisp P, Clissold SP. Foscarnet. Drugs. 1991; 41:104-29.
53. Youle MS, Clarbour J, Gazzard B et al. Severe hypocalcaemia in AIDS patients treated with foscarnet and pentamidine. Lancet. 1988; 331:1455-6.
54. Ljungman P, Deliliers GL, Platzbecker U et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. Blood. 2001; 97:388-92. (Pubitemid 32060322)
55. Chakrabarti S, Collingham KE, Osman H et al. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections. Bone Marrow Transplant. 2001; 28:879-81. (Pubitemid 33107616)
56. Baber N, Halliday L, Sibeon R et al. The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study. Clin Pharmacol Ther. 1978; 24:298-307.
57. Upton RA, Williams RL, Buskin JN et al. Effects of probenecid on ketoprofen kinetics. Clin Pharmacol Ther. 1982; 31:705-12. (Pubitemid 13096683)
58. Shukla UA, Pittman KA, Barbhaiya RH. Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. J Clin Pharmacol. 1992; 32:725-31.
59. McNamara PJ, Trueb V, Stoeckel K. Ceftriaxone binding to human serum albumin. Indirect displacement by probenecid and diazepam. Biochem Pharmacol. 1990; 40:1247-53.
60. Sanchez G. Enhancement of heparin effect by probenecid. N Engl J Med. 1975; 292:48. Letter.
61. Aherne GW, Piall E, Marks V et al. Prolongation and enhancement of serum methotrexate concentrations by probenecid. Br Med J. 1978; 1:1097-9. (Pubitemid 8319298)
62. Basin KS, Escalante A, Beardmore TD. Severe pancytopenia in a patient taking low-dose methotrexate and probenecid. J Rheumatol. 1991; 18:609-10.
63. Limaye AP. Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients. Semin Respir Infect. 2002; 17:265-73. (Pubitemid 35453643)
64. Chong AS, Zeng H, Knight DA et al. Concurrent antiviral and immunosuppressive activities of leflunomide in vivo. Am J Transplant. 2006; 6:69-75. (Pubitemid 43382202)
65. Williams JW, Mital D, Chong A et al. Experiences with leflunomide in solid organ transplantation. Transplantation. 2002; 73:358-66. (Pubitemid 34174284)
66. Arava (leflunomide) package insert. Bridgewater, NJ: Sanofi-Aventis; 2007.
67. Hill CL. Leflunomide-induced peripheral neuropathy: rapid resolution with cholestyramine wash-out. Rheumatology. 2004; 43:809. (Pubitemid 38807444)
68. Chonlahan J, Halloran MA, Hammonds A. Leflunomide and warfarin interaction: case report and review of the literature. Pharmacotherapy. 2006; 26:868-71. (Pubitemid 43807637)
69. Snydman DR, Werner BG, Heinze-Lacey BH et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipients. N Engl J Med. 1987; 317:1049-54. (Pubitemid 17160541)
70. Snydman DR, Werner BG, Dougherty NN et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1993; 119:984-91.
71. Ham JM, Shelden SR, Godkin RR et al. Cytomegalovirus prophylaxis with ganciclovir, acyclovir and CMV hyperimmune globulin in liver transplant patients receiving OKT3 induction. Transplant Proc. 1995; 27(suppl 1):31-3.
72. Avery RK, Michaels M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am J Transplant. 2008; 8:9-14.